Grifols (GRFS) Net Income Growth (3y) (2013 - 2020)
Grifols (GRFS) Net Income Growth (3y) (2013 - 2020) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.47% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 39.28% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 12.02% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.11% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 19.87% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -129.59% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -28.09% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -57.91% |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 10.02% |
| Dec 31, 2019 | 66.31% |
| Mar 31, 2019 | -20.06% |
| Dec 31, 2018 | 131.55% |
| Jun 30, 2018 | 6.57% |
| Mar 31, 2018 | -4.73% |
| Dec 31, 2017 | 54.10% |
| Jun 30, 2017 | 1,116.31% |
| Mar 31, 2017 | -1.30% |
| Dec 31, 2016 | -8.21% |
| Sep 30, 2016 | 27.24% |
| Jun 30, 2016 | 4.79% |
| Mar 31, 2016 | 32.10% |
| Dec 31, 2015 | -44.27% |
| Sep 30, 2015 | 42.65% |
| Jun 30, 2015 | 6.94% |
| Mar 31, 2015 | 18.99% |
| Dec 31, 2014 | -296.26% |
| Sep 30, 2014 | 72.18% |
| Jun 30, 2014 | 26.07% |